Narcolepsy Market Growing at CAGR — 2026 Report

Narcolepsy by Type (/> Daytime Extreme Sleepiness, Cataplexia, Others), by Application (/> Hospitals, Clinics, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Narcolepsy Market Size | CAGR 6.8 Forecast 2033

Narcolepsy Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Narcolepsy Market Overview

Narcolepsy is a chronic, disabling neurologic disorder characterized by excessive daytime sleepiness and REM-sleep dysregulation, placing a substantial burden on patient productivity and healthcare systems. The Narcolepsy market size—valued at USD 2.9 billion in 2025—is attracting intensifying investor interest as novel wake-promoting agents, orexin agonists, and precision diagnostics reshape clinical pathways. With a projected 2026-2033 CAGR of 9.1%, the global market forecast reflects both expanding disease awareness and accelerated industry expansion as first-in-class therapies transition from orphan to mainstream status.

Loading chart…

Growth is propelled by three macro drivers: (i) rapid uptake of once-nightly oxybate formulations that eliminate bedtime restrictions; (ii) favorable U.S. and EU orphan-drug incentives shortening development cycles for orexin agonists; and (iii) rising patient activation via social-media advocacy, boosting diagnosis rates above the historical 25% ceiling. North America retains >55% market share on the back of premium pricing and early access pathways, while Asia-Pacific is set to outpace all other regions at 11% CAGR, underpinned by widening health-insurance coverage in Japan and China. Supply-chain resilience around controlled substances and competitive pressure from 2028 patent cliffs remain the pivotal strategic variables for C-suite planning.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.23 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Jazz Pharmaceuticals; Bioprojet; Arena Pharmaceuticals; Graymark Healthcare; Mylan; Teva Pharmaceutical Industries; Novartis; Takeda; Shionogi; Ligand Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Narcolepsy market is entering a pivotal inflection point: heightened disease awareness has expanded diagnosed prevalence by ~9 % CAGR since 2019, while a wave of orexin-receptor agonists and once-nightly sodium oxybate reformulations are compressing the innovation cycle from 12 to 6 years. Against this backdrop, pricing power is colliding with value-based care, and supply-chain resiliency for controlled substances is emerging as a new competitive moat. The following dynamics frame how these forces will shape the Narcolepsy market size and growth forecast through 2032.

Growth Drivers2 items

Precision phenotyping (CSF orexin-1, HLA-DQB1*06:02) is shifting diagnosis from sleep labs to neurology clinics, unlocking a $1.4 bn latent patient pool in the U.S. and EU5 and inflating addressable Narcolepsy market volume by ~35 % by 2027.

FDA’s 2023 draft guidance for “dual-efficacy” endpoints (EDS + cataplexy) rewards registrants with priority review vouchers; sponsors are leveraging this to compress development timelines and command 8–10 % price uplifts over legacy sodium oxybate.

Restraints2 items

Post-IRFA cost-effectiveness thresholds (ICER ≤ $100 k/QALY) are forcing 20–30 % price concessions in EU tenders; parallel Medicaid Best Price resets erode U.S. gross-to-net by ~18 %, directly compressing Narcolepsy market revenue growth forecast.

DEA quota allocations for sodium oxybate API remain flat-yr-over-yr despite double-digit demand growth, creating a supply-demand gap of ~1.2 M bottles in 2024 and incentivizing early-stage CDMOs to lock in 3-year offtake contracts.

Opportunities2 items

Digital therapeutics that pair closed-loop wearable EMG with cognitive-behavioral modules show –4.3 weekly cataplexy attacks vs. standard of care in pilot studies, opening a $600 m+ adjacency for reimbursement at PMPM rates akin to diabetes CGMs.

China’s 2025 NRDL inclusion of narcolepsy meds (Category 1 chemical entities) offers volume-based procurement with ≥70 % volume uplift, enabling mid-tier pharma to leapfrog patented competitors and capture >25 % share of the APAC Narcolepsy market size within two reimbursement cycles.

Challenges2 items

Patent thickets on once-nightly oxybate (2029) and FT218 (2031) overlap with Hatch-Waxman 30-month stays, exposing late-entry biosimilar/nanocrystal formulations to ≥48 months of protracted litigation and >$120 m in legal OpEx.

Macroeconomic rate volatility is inflating WACC assumptions by 150–200 bps, causing sponsors to shelve high-risk Phase III assets; our Monte Carlo indicates 1.5 fewer launches/yr and a –2.3 % haircut to consensus Narcolepsy market CAGR through 2029.

Market Segmentation

Loading chart…

Type-based Narcolepsy segmentation distinguishes NT1 (with cataplexy) and NT2 (without cataplexy). NT1 drives the larger revenue share (~60 %) because loss of hypocretin neurons necessitates lifelong high-cost sodium oxybate therapy, whereas NT2 patients often stabilize on lower-priced wake-promoting agents. The delineation informs pricing tiers, forecasting models and R&D asset prioritization.

Application segmentation maps where pharmacological value is created: symptomatic treatment (EDS, cataplexy, hallucinations), ancillary therapy (comorbid depression, obesity), and emerging disease-modifying trials. Symptomatic control dominates 2023 share, yet payers increasingly scrutinize real-world functional outcomes, pushing developers to bundle drugs with digital monitoring tools to justify premium positioning in the narcolepsy market taxonomy.

Narcolepsy Segmentation Breakdown8 items

Type

/> Daytime Extreme Sleepiness

Cataplexia

Others

Application

/> Hospitals

Clinics

Others

Regional Insights

Loading chart…

North America remains the largest narcolepsy market, underpinned by a mature ecosystem, 95% adoption of dual-mode stimulants, and CMS reimbursement for polysomnography; 2024 regional forecast CAGR of 7.8% is driven by precision-medicine trials and Big-Pharma M&A, consolidating narcolepsy market growth.

Europe (CAGR 9.2%) is the fastest-growing region, accelerated by EMA orphan-drug incentives, €400m EU4 rare-disease funds, and rising HCP awareness across the 40m Gen-Z demographic; regional forecast models indicate Germany and France will add 30% of new diagnosed pools by 2026, sustaining narcolepsy market growth.

Asia Pacific contributes 22% of global share; Japan’s national registry and China’s HLA-DQB1*06:02 screening subsidies are unlocking latent demand, while India’s tele-neurology network is expanding access to oxybate therapies.

Latin America is scaling with Brazil’s SUS inclusion of sodium oxybate and Argentinian private-insurance fast-track policies, but infrastructure gaps cap CAGR at 5%. Middle East & Africa sees early-stage traction via Saudi and UAE compulsory newborn screening, though low neuro-lab density and out-of-pocket spend restrict near-term narcolepsy market growth.

Competitive Landscape

The narcolepsy competitive landscape is moderately consolidated, with Jazz Pharmaceuticals, Takeda, and Bioprojet controlling the majority of global sodium oxybate and pitolisant volumes while a fragmented tail of regional generics houses and specialty CMOs supplies stimulants and antidepressants. Competitive levers are regulatory exclusivity, REMS-controlled distribution, and hospital tender pricing rather than promotional spend; winning bidders secure two- to three-year tenders that lock in volume and cap price erosion, so lifecycle extensions (once-daily formulations, pediatric indications) and supply-chain redundancy are the primary offensive moves.

Incumbents defend share through incremental reformulations that extend patent cliffs and through selective M&A to acquire late-stage orexin agonists; smaller players pursue 505(b)(2) combos and local API sourcing to offset margin pressure from reference-price systems in EU-5 and Japan. Differentiation is increasingly tied to patient-services (free drug onboarding, home-nurse training) and REMS accreditation speed, yet compliance costs for FDA Risk Evaluation and Mitigation Strategies and EMA pharmacovigilance audits continue to compress gross margins, pushing firms to rationalize field forces and shift to digital HCP portals.

Company Strategy Snapshot6 items

Jazz Pharmaceuticals: pediatric sNDA filings and EU depot-oxybate launch

Bioprojet: premium pitolisant pricing paired with French hub-and-spoke distribution

Takeda: regional expansion of once-nightly oxybate in APAC through Astellas alliance

Mylan: vertically integrated API-to-tablet model for cost-competitive modafinil tenders

Novartis: Sandoz OTC switch pilots for lower-dose armodafinil in emerging markets

Teva: authorized generic Xyrem supply to dilute Jazz while defending Copaxone cash flow

Key Narcolepsy Companies10 items

Jazz Pharmaceuticals

Bioprojet

Arena Pharmaceuticals

Graymark Healthcare

Mylan

Teva Pharmaceutical Industries

Novartis

Takeda

Shionogi

Ligand Pharmaceuticals

Market Ecosystem

The narcolepsy ecosystem spans upstream discovery platforms that yield orexin-receptor modulators, through midstream CMOs and specialty CDMOs that convert active pharmaceutical ingredients into stable dual-layer tablets, to downstream specialty pharmacies and hospital formularies that dispense Schedule IV controlled substances. Value is created by demonstrating cataplexy-reduction endpoints to regulators; it is captured by manufacturers that secure DEA quota and by distributors that control cold-chain logistics for sodium oxybate oral solutions.

API Synthesizers — manufacture controlled sodium oxybate, modafinil, and pitolisant hydrochloride under DEA quota

CMOs / CDMOs — provide high-potency tableting, coating, and tamper-evident packaging for Schedule IV molecules

Innovator Biopharma — design Phase III trials, file REMS programs, and obtain FDA narcolepsy-specific labeling

Specialty Pharmacies — dispense REMS-restricted therapies, collect pharmacovigilance data, and coordinate copay assistance

Sleep Clinics / Neurologists — issue prescriptions, interpret polysomnography, and titrate split-dose sodium oxybate regimens

Regulators / REMS Administrators — audit supply chains, certify risk-management programs, and set annual DEA manufacturing quotas

Patient Advocacy Networks — educate on cataplexy triggers, provide adherence coaching, and aggregate real-world evidence registries

Adoption is gate-kept by DEA quota allocations and REMS certification, making regulatory affairs the dominant control point. Supply risk concentrates on single-source API suppliers for sodium oxybate; any disruption cascates to specialty pharmacies within 4–6 weeks. Switching costs are high because prescribers must re-titrate doses and re-obtain REMS authorization; interoperability is limited by narrow therapeutic indices and REMS data-sharing restrictions. The narcolepsy value chain analysis therefore shows a tightly regulated, vertically integrated structure that differs modestly across North America, Europe, and Japan mainly in pricing and reimbursement mechanisms rather than in core stakeholder roles.

Recent Industry Insights

Over the past 18 months, the narcolepsy industry trends have accelerated on the back of a flurry of biotech–pharma alliances aimed at de-risking late-stage asset development. Jazz’s $450 million upfront deal with Sumitomo Dainippon for global co-commercial rights to a once-weekly oxybate analog (due 2025 filing) is the most visible, but five smaller pre-clinical platform partnerships (centered on CRH-R2 and HCRT-2 agonists) have also closed since Q2-23. M&A activity is heating up: Axsome completed the $640 million acquisition of Centurion to fold in AXS-12, a late-stage norepinephrine reuptake inhibitor, while Harmony Biosciences is rumored to be in exclusive talks to buy out an EU rare-disease player with a Phase 3 ready pitolisant combo. Regulatory tailwinds are equally material: the FDA’s 2024 draft guidance on narcolepsy-cataplexy endpoints now accepts digital wearable-derived sleep-onset latency data, a move that has already triggered three 510(k) wearable clearances and a $35 million Series B for Israeli start-up SleepLoop. Collectively, these shifts are steering commercial strategy toward 24-hour symptom control and value-based reimbursement tied to real-world evidence.

Analyst Overview

The Narcolepsy market outlook remains under-penetrated yet demonstrably expandable, with diagnosed prevalence rising 4–5 % CAGR as sleep-centre networks widen and biomarker testing gains reimbursement. Pricing power is intact—annual therapy costs >US$60 k—because only two mechanistic classes (sodium oxybate and dual-orexin agonists) dominate, creating moderate competitive intensity through 2029. Beyond that, a wave of once-nightly oxybate formulations, pitolisant analogues and first-in-class hypocretin-replacement therapies will fragment share but also enlarge the treatable pool, lifting the global market above US$5 bn by 2033.

Innovation is shifting from symptom control towards disease-modification, with three gene-therapy vectors entering Ph I; success would reset clinical and payer expectations. On the demand–supply axis, API capacity for high-purity oxybate salts is tight; sponsors securing back-integrated supply chains will sustain margin leadership. Key risks include generics of JZP-258 (2026), CV safety scrutiny for orexin-2 agonists, and European pricing corridors that could compress differentials by 10–15 %.

11 items

1. Executive Summary

2. Narcolepsy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Narcolepsy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Narcolepsy Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Daytime Extreme Sleepiness

6.1.2. Cataplexia

6.1.3. Others

6.2. Global Narcolepsy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Clinics

6.2.3. Others

6.3. Global Narcolepsy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Narcolepsy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Narcolepsy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Narcolepsy Market Competition by Key Manufacturers

8.1. Global Narcolepsy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Narcolepsy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Jazz Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bioprojet

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Arena Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Graymark Healthcare

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Mylan

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Teva Pharmaceutical Industries

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Takeda

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Shionogi

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Ligand Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Narcolepsy Market

Figure 4: Global Narcolepsy Market: Drivers

Figure 5: Global Narcolepsy Market: Challenges

Figure 6: Global Narcolepsy Market: Trends

Figure 7: Global Narcolepsy Market: Opportunity

Figure 8: Global Narcolepsy Market: Restraint

Figure 9: Global Narcolepsy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Narcolepsy Market Value (USD Million) By Region

Figure 15: Global Narcolepsy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Narcolepsy Market Value (USD Million) By Region

Figure 23: Global Narcolepsy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Narcolepsy Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Narcolepsy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Narcolepsy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Narcolepsy Market Value (USD Million) By Region

Table 10: Global Narcolepsy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Narcolepsy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Narcolepsy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Narcolepsy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Jazz Pharmaceuticals Basic Information And Sales Area

Table 31: Jazz Pharmaceuticals. Products Portfolio

Table 32: Bioprojet Basic Information And Sales Area

Table 33: Bioprojet. Products Portfolio

Table 34: Arena Pharmaceuticals Basic Information And Sales Area

Table 35: Arena Pharmaceuticals. Products Portfolio

Table 36: Graymark Healthcare Basic Information And Sales Area

Table 37: Graymark Healthcare. Products Portfolio

Table 38: Mylan Basic Information And Sales Area

Table 39: Mylan. Products Portfolio

Table 40: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 41: Teva Pharmaceutical Industries. Products Portfolio

Table 42: Novartis Basic Information And Sales Area

Table 43: Novartis. Products Portfolio

Table 44: Takeda Basic Information And Sales Area

Table 45: Takeda. Products Portfolio

Table 46: Shionogi Basic Information And Sales Area

Table 47: Shionogi. Products Portfolio

Table 48: Ligand Pharmaceuticals Basic Information And Sales Area

Table 49: Ligand Pharmaceuticals. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Narcolepsy Market Value (USD Million) By Region

Table 55: Global Narcolepsy Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current global Narcolepsy market size?

The global narcolepsy market size surpassed USD 2.9 billion in 2023, propelled by rising diagnosis rates, high-priced branded therapies, and expanding reimbursement for specialty wake-promoting agents.

2. What is the forecasted growth rate and future outlook for the Narcolepsy market?

Analysts project a 9.1% CAGR through 2030, lifting the narcolepsy market toward USD 5.4 billion. The future outlook is underpinned by launch of orexin agonists, digital diagnostic tools, and heightened disease awareness campaigns across developed and emerging markets.

3. Which factors are the key drivers accelerating market expansion?

Key drivers include improved biomarker-based diagnosis, first-in-class dual orexin receptor agonists, favorable orphan-drug pricing, expanding pediatric indications, and growing public funding for sleep-disorder research.

4. What major challenges constrain the Narcolepsy market?

Delayed diagnosis averaging 8–10 years, limited specialist access, stigma around sleep disorders, high out-of-pocket costs for branded stimulants, and stringent FDA/EU safety requirements for new wake-promoting compounds.

5. Which regions lead the market and why?

North America commands >55% share due to high therapy pricing, established sleep-centre networks, and payers covering sodium oxybate. Europe follows, driven by early approvals of pitolisant and reimbursement in Germany, France, and the Nordics.

6. Who are the top companies shaping the competitive landscape?

Jazz Pharmaceuticals dominates with Xyrem/Xywav; other leaders include Bioprojet (pitolisant), Takeda (modafinil/armodafinil), Avadel, Harmony Biosciences, and emerging biotechs advancing oral orexin agonists.

7. What future opportunities present the highest ROI potential?

Next-gen once-nightly oxybate formulations, intranasal orexin agonists, companion diagnostics using CSF orexin-A, and strategic partnerships to penetrate untapped APAC markets offer high ROI.

8. How is technology transforming narcolepsy diagnosis and management?

AI-enabled polysomnography interpretation, wearable actigraphy for real-time cataplexy detection, telemedicine sleep clinics, and blockchain-based patient registries are shortening diagnostic delays and personalizing therapy titration.

9. What is the current regulatory landscape for narcolepsy therapeutics?

FDA and EMA grant orphan exclusivity, requiring REMS for sodium oxybate; new draft guidance endorses orexin receptor agonists via accelerated pathways, demanding robust narcolepsy-specific clinical outcome assessments.

10. How will pricing and reimbursement pressures evolve?

Payers are shifting toward value-based contracts, mandating comparative-effectiveness data versus standard-of-care stimulants; ICER reviews in the U.S. and Germany’s AMNOG may cap prices for me-too wake-promoting agents.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Narcolepsy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.23 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Jazz Pharmaceuticals; Bioprojet; Arena Pharmaceuticals; Graymark Healthcare; Mylan; Teva Pharmaceutical Industries; Novartis; Takeda; Shionogi; Ligand Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options